Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials

Table 8 Subgroup analysis of different BMI

BMI	Outcome	No. of studies	Pooled sample size	Heterogeneity			Overall effect
		No. of studies	Pooled sample size	T²	I²	P-value	SMD [95% CI]	P-value
BMI < 27	BMI	7	618	0.83	94%	<0.00001	-0.27 [-0.98, 0.43]	0.45
	SBP	3	381	0.09	72%	0.03	0.20 [-0.21, 0.60]	0.34
	DBP	3	381	0.10	74%	0.02	0.15 [-0.27, 0.57]	0.48
	FPG	7	788	0.02	38%	0.14	-0.05 [-0.24, 0.13]	0.57
	HbA1c	6	720	0.00	0%	0.43	0.06 [-0.09, 0.20]	0.43
	PPBS	4	276	0.23	780%	0.003	-0.38 [-0.91, 0.15]	0.16
	TC	5	455	0.37	88%	<0.00001	0.26 [-0.31, 0.84]	0.37
	HDL	5	455	0.57	92%	<0.00001	0.11 [-0.58, 0.81]	0.75
	LDL	3	340	0.08	65%	0.06	0.30 [-0.09, 0.70]	0.14
	TG	5	455	0.13	72%	0.006	0.33 [-0.05, 0.71]	0.09
	FINS	5	352	0.21	78%	0.001	-0.17 [-0.63, 0.29]	0.47
BMI ≥ 27	BMI	3	370	0.13	79%	0.009	0.31 [-0.15, 0.78]	0.18
	SBP	2	234	0.42	91%	0.001	0.69 [-0.25, 1.63]	0.15
	DBP	2	234	0.47	92%	0.0005	0.63 [-0.36, 1.63]	0.21
	FPG	2	300	0.00	0%	0.82	0.34 [0.11, 0.57]	0.003
	HbA1c	2	300	0.27	91%	0.001	0.17 [-0.58, 0.93]	0.65
	PPBS	2	300	0.01	29%	0.24	0.09 [-0.18, 0.36]	0.51
	TC	3	370	0.02	30%	0.24	0.33 [0.08, 0.58]	0.01
	HDL	3	370	0.00	0%	0.71	0.03 [-0.18, 0.23]	0.79
	LDL	2	300	0.00	6%	0.30	0.32 [0.08, 0.56]	0.008
	TG	3	370	0.00	4%	0.35	0.15 [-0.06, 0.36]	0.17
	FINS	3	370	0.76	95%	<0.00001	0.56 [-0.45, 1.57]	0.28

ISSN: 1758-5996